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Beta-Blockers and Microvolt T-Wave Alternans. Introduction: Results of microvolt T-wave
alternans (MTWA) studies vary and may be influenced by whether beta-blocker therapy was withheld
prior to MTWA assessment. We conducted a meta-analysis of the predictive value of MTWA screening
for ventricular arrhythmic events in primary prevention patients with left ventricular dysfunction and
examined whether results differed depending upon whether beta-blocker use was withheld prior to MTWA
testing.
Methods and Results: Prospective studies that evaluated whether MTWA predicted ventricular arrhyth-
mic events published between January 1980 and September 2008 were identified. Summary estimates for
the predictive value of MTWA were derived with random-effects models. Nine studies involving 3,939 pa-
tients were identified. Overall, an abnormal MTWA (positive and indeterminate) test was associated with
an almost 2-fold increased risk for arrhythmic events (pooled RR = 1.95, 95% CI: 1.29–2.96; P = 0.002).
However, significant heterogeneity across studies was observed (P = 0.024). In the 4 studies in which beta-
blocker therapy was not withheld prior to MTWA assessment, an abnormal MTWA test was associated
with a 5-fold increased risk for arrhythmic events (pooled RR = 5.39, 95% CI: 2.68–10.84; P < 0.001) and
was robust to sensitivity analyses. In contrast, the association was much weaker in those studies where the
use of beta-blocker therapy was withheld prior to MTWA testing (pooled RR = 1.40, 95% CI: 1.06–1.84;
P = 0.02).
Conclusions: In primary prevention patients with left ventricular dysfunction, the predictive power
of MTWA varied widely, based on whether beta-blocker therapy was withheld prior to its assessment.
This observation may explain the inconsistent results of MTWA studies in this population. (J Cardiovasc
Electrophysiol, Vol. 21, pp. 1009-1014, September 2010)
beta-blocker, microvolt T-wave alternans, cardiomyopathy, prognosis, sudden death
Background
Implantable cardioverter defibrillator (ICD) therapy has
been shown to reduce mortality among primary prevention
patients with left ventricular dysfunction.1,2 However, en-
thusiasm for their use has been tempered by high initial
costs, device complication rates,3,4 and recent manufacturer
recalls.5,6 Given these concerns and because as few as 1 in 5
patients receives a therapeutic defibrillation from their ICD,2
there is great interest in further risk stratification of patients
at risk for sudden cardiac death. Microvolt T-wave alternans
(MTWA), which detects abnormalities in ventricular repo-
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larization that are associated with the onset of ventricular
arrhythmias,7,8 has been proposed as a method to improve
the efficient use of ICD therapy by identifying patients at
highest risk for sudden cardiac death.9,10
Although a prior meta-analysis found that MTWA predicts
ventricular arrhythmic events among patients with ischemic
and nonischemic heart failure,11 recent studies have reported
less consistent results.12-15 Notably, studies of MTWA var-
ied in their screening protocols as to whether beta-blocker
therapy was withheld prior to testing, despite evidence that
beta-blockers suppress MTWA amplitude and affect the pres-
ence of MTWA during testing.16 Indeed, 1 in 6 patients who
screened MTWA positive when beta-blocker therapy was
withheld converted to a negative test result during re-testing
on beta-blocker therapy,16 and the amplitude of MTWA is
significantly decreased by acute beta-blockade.17 Under ideal
circumstances, a screening test for prognostication should be
performed in a pharmacologic environment consistent with
the patient’s medical therapy to ensure that test results reflect
the potential benefits of chronic drug therapy. Differences in
protocols between MTWA studies regarding discontinuation
of beta-blocker therapy prior to testing may therefore lead to
discordant results.
Accordingly, we performed a meta-analysis to assess for
heterogeneity in prognosis among MTWA studies of primary
prevention patients with left ventricular dysfunction and, if
present, assessed whether the ability of MTWA to predict
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ventricular arrhythmic events varied based on whether beta-
blocker therapy was withheld prior to testing.
Methods
Study Inclusion Criteria and Outcome Measures
A systematic review of the literature was conducted to
identify prospective studies that: (1) evaluated MTWA in
patients with left ventricular systolic dysfunction (ejection
fraction ≤40%) and no prior sustained ventricular arrhyth-
mia or cardiac arrest; (2) used a standard noninvasive MTWA
screening protocol (i.e., electrophysiologic assessments of
MTWA were excluded); (3) had a minimum of 6 months of
follow-up and at least 100 patients in the study; (4) provided
clear definitions of normal and abnormal MTWA results;
and (5) provided sufficient quantitative data on the study out-
come of ventricular arrhythmic events. Ventricular arrhyth-
mic events were defined as any event involving ventricular
tachycardia or fibrillation, cardiac arrest, arrhythmic death,
and appropriate ICD shocks.
Data Sources and Search Strategy
We searched for published studies in the English lan-
guage between January 1 1980 through September 30 2008
using PubMed, EMBASE, and all EBM Reviews (which in-
cluded Cochrane Database of Systematic Reviews, Database
of Abstracts and Reviews of Effects, ACP Journal Club,
Cochrane Central Register of Controlled Trials, Cochrane
Methodology Register, and Health Technology Assessment).
The search used both key words and MeSH terms using a
Boolean Search Strategy and included the following medi-
cal subject headings: prospective studies, follow-up studies,
T-wave alternans, prognosis, predictive value of tests, sud-
den death, ventricular fibrillation, ventricular tachycardia,
and ICD shocks. In addition, a hand search of bibliographies
of key articles identified through the automated search was
performed.
Data Extraction
Data extraction was performed by a study author (PSC)
using a pre-piloted, standardized form. From each study,
the following variables were abstracted: year of publica-
tion; number of study centers; study sample size; withholding
of beta-blocker therapy prior to MTWA screening; etiology
of left ventricular dysfunction; proportion of study patients
treated with beta-blockers; proportion of patients with abnor-
mal and normal MTWA test results; and proportion of study
patients with ICDs. Information on whether beta-blocker
therapy was withheld prior to MTWA screening was ob-
tained from investigators through electronic mail when not
reported in published articles.12,18,19 When results from more
than one follow-up time period were reported (e.g., at 1 year
and 2 years),15 we used estimates from the longer follow-up
period.
Statistical Analysis
Consistent with prior work, we compared outcomes be-
tween patients with MTWA abnormal (positive and in-
determinate) and normal (negative) studies.20,21 Data for
the outcome of ventricular arrhythmic events were sum-
marized using basic descriptive statistics (simple counts
and proportions). A meta-analysis was conducted using a
random-effects model with the restricted maximum likeli-
hood method developed by DerSimonian and Laird.22 To
evaluate for heterogeneity between studies, we calculated
Cochran’s Q test and I2, which represents the degree of in-
consistency among studies. We focused on unadjusted results
to be consistent, because not all studies performed multivari-
able analyses. One study reported no events in patients with
normal MTWA,18 and so we assigned a non-zero (0.5) cor-
rection factor to calculate its relative risk ratio.23 Publication
bias was evaluated using the Begg’s test.
Since we hypothesized a priori that withholding beta-
blocker therapy prior to MTWA testing would lead to signif-
icant heterogeneity across the trials, we report our findings
stratified by this category using subgroup analyses. Addi-
tional subgroup analyses were conducted to explore the het-
erogeneity in risk ratios between studies based upon other
study criteria, which included: proportion of study patients
with ICDs (low [<40%] vs high [≥40%]); time period of
publication (before vs since 2006); number of study centers
(<10 vs ≥10); and etiology of left ventricular dysfunction
(ischemic, nonischemic, or both). Finally, we performed sen-
sitivity analyses to examine the influence of each study on
the pooled estimate by omitting each study one at a time. All
statistical tests were 2-sided and were evaluated at a signif-
icance level of 0.05. STATA version 10.0 (College Station,
TX, USA) was used to conduct all analyses.
Results
Nine studies involving 3,939 patients met study inclusion
criteria.10,12-15,18,19,24,25 Of these, 4 conducted MTWA test-
ing on beta-blocker therapy, while 5 withheld beta-blocker
therapy for at least 24 hours prior to testing (Table 1). Four of
the studies were conducted among patients with left ventric-
ular dysfunction due to an ischemic etiology, 3 were among
patients with a nonischemic etiology, and 2 were among pa-
tients with either an ischemic or nonischemic etiology. Six
of the studies were multicentered trials, while 3 were single
institution studies.
Results from the individual studies are summarized in
Table 2. Overall, 5 studies found an association between
an abnormal MTWA test and increased risk for ventricular
arrhythmic events.10,14,18,19,25 Individual study hazard ratios
(HRs) for the 9 studies ranged from 1.11 (95% confidence in-
terval [CI]: 0.63–1.95) to 6.53 (95% CI: 2.35–18.11). When
the results from all 9 studies were pooled, an abnormal
MTWA result was associated with a 2-fold increased risk
for ventricular arrhythmic events (pooled risk ratio [RR] of
1.95, 95% CI: 1.29–2.96; P = 0.002). However, significant
heterogeneity was present in the overall pooled estimate (P =
0.024).
Because of the heterogeneity across studies, we stratified
our analyses based on our a priori criteria of whether beta-
blocker therapy was withheld prior to MTWA assessment.
Among studies where the use of beta-blockers was contin-
ued during MTWA testing,14,18,19,25 an abnormal MTWA test
was associated with a greater than 5-fold increased risk for
ventricular arrhythmic events (pooled RR of 5.39, 95% CI:
2.68–10.84; P < 0.001) (Fig. 1). This result was robust to sen-
sitivity analyses when each study was systematically elim-
inated one at a time. In contrast, the association was much
weaker in those studies where the use of beta-blocker therapy
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TABLE 1
Characteristics of Prospective Studies of Microvolt T-Wave Alternans in Primary Prevention Patients with Left Ventricular Dysfunction
Number Mean Beta-Blocker Proportion on Proportion
Year of Number of Population of Follow-Up Withheld Prior to on Beta- with
Study Publication Centers Type Patients (months) Testing? Blockers, % ICDs, %
Klingenheben18 2000 1 Ischemic 107 15 No Not reported 0
Hohnloser19 2003 1 Nonischemic 137 14 No Not reported 27
Grimm24 2003 1 Nonischemic 263 52 Yes 73 0
Bloomfield25 2006 11 Both 587 24 No 81 12
Chow10 2006 7 Ischemic 768 18 Yes 82 51
ALPHA14 2007 9 Nonischemic 446 19 No 80 8
SCD-HeFT13 2008 37 Both 490 35 Yes 74 34
MASTER12 2008 50 Ischemic 575 26 Yes 87 100
ABCD15 2009 42 Ischemic 566 24 Yes 86 87
ICD = implantable cardioverter defibrillator.
was withheld prior to MTWA testing10,12,13,15,24 (pooled RR
of 1.40, 95% CI: 1.06–1.84; P = 0.02; Fig. 1) and was not
robust to sensitivity analysis when a key study10 was elimi-
nated (pooled RR = 1.27, 95% CI: 0.96–1.68; P = 0.10). In
both subgroups, stratifying results by whether beta-blocker
therapy was withheld prior to MTWA assessment eliminated
the presence of statistical heterogeneity in the pooled anal-
yses (P for heterogeneity = 0.84 for studies not withhold-
ing beta-blockers and P for heterogeneity = 0.38 for studies
withholding beta-blockers). Notably, all 4 studies that did not
find an increased risk of ventricular arrhythmic events with
an abnormal MTWA result had withheld use of beta-blocker
therapy prior to MTWA testing.12,13,15,24
The sensitivity, specificity, positive predictive value, and
negative predictive value (NPV) of MTWA testing for each
individual study and stratified by whether beta-blocker use
was withheld prior to MTWA testing are depicted in Table 3.
In the 5 studies where beta-blocker therapy was withheld
prior to testing, MTWA screening yielded an overall sensi-
tivity of 77% and an NPV of 91% for predicting ventricular
arrhythmic events during follow-up. In contrast, in the 4 stud-
ies where beta-blocker therapy was continued during testing,
MTWA screening yielded an overall sensitivity of 92% and
an NPV of 98%.
Finally, subgroup analyses found that use of beta-blocker
therapy during MTWA assessment was the variable that best
TABLE 2
Results of Prospective Studies of Microvolt T-Wave Alternans in Primary Prevention Patients with Left Ventricular Dysfunction
MTWA Abnormal MTWA Normal Hazard Ratio
Study N Event No Event N Event No Event (95% CI)
Klingenheben18 74 13 61 33 0 33 Undefined†
Hohnloser19 103 16 87 34 2 32 3.44 (0.03–459.0)
Grimm24 191 31 160 72 7 65 1.30 (0.59–2.90)
Bloomfield25 360 51 309 189 4 185 6.53 (2.35–18.11)
Chow10 514 57 457 254 11 243 2.93 (1.33–6.46)
ALPHA14 292 29 263 154 4 150 4.01 (1.41–11.41)
SCD-HeFT13 355 59 296 135 16 119 1.11 (0.63–1.95)
MASTER12 361 48 313 214 22 192 1.26 (0.76–2.09)
ABCD15 401 49 352 165 16 149 1.4 (0.8–2.2)‡
MTWA = microvolt T-wave altnernans.
†Hazard ratio undefined as there were no events in the MTWA normal group.
‡Two-year outcomes obtained from study authors.
explained the statistical heterogeneity in prognosis among
the MTWA studies (Table 4). Most notably, the pooled RR
among studies with a low (<40%) proportion of patients with
ICDs was not substantially different among studies with a
high (≥40%) proportion of patients with ICDs.
Discussion
We found a significant association between an abnormal
MTWA test and increased risk for ventricular arrhythmic
events among primary prevention patients with left ventricu-
lar dysfunction in the current literature, but also noted signif-
icant heterogeneity across these trials. Notably, studies con-
tinuing use of beta-blocker therapy during MTWA testing
showed a stronger and more consistent 5-fold increased risk
for ventricular arrhythmic events, whereas a much weaker
relationship was observed among studies withholding beta-
blocker therapy prior to MTWA testing.
In prior work, administration of beta-blocker therapy at
the time of MTWA testing was found to significantly reduce
the amplitude of MTWA.16,17 One in 6 patients with a posi-
tive MTWA test off beta-blockers converted to a normal test
result upon rescreening on beta-blocker therapy, as their max-
imal T-wave amplitude had decreased below the threshold of
1.9 mV for a positive test.16 Another study found that 1 in 2
patients with a positive MTWA result converted to a normal
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Figure 1. Association between MTWA and ventricular arrhythmic events, stratified by screening protocol discontinuation of beta-blocker therapy. Significant
heterogeneity was observed among studies (P = 0.025). Subgroup analyses found a strong, consistent, 5-fold increased for ventricular arrhythmic events in
studies where beta-blocker therapy was not discontinued prior to MTWA assessment. In contrast, a weak association between an abnormal MTWA test and
risk for arrhythmic events was observed in studies that withheld beta-blocker therapy prior to MTWA assessment.
test result upon administration of beta-blocker therapy.17 A
third study found that beta-blocker administration resulted in
a negative MTWA test result in 8 of 26 (30.8%) patients who
initially screened positive.26 Because beta-blockers may alter
the development of MTWA results, they may also modulate
susceptibility to ventricular arrhythmias. Indeed, it has been
argued that MTWA testing should be performed on beta-
blocker therapy to provide a risk stratification that more reli-
ably reflects the ‘pharmacologic milieu’ of the patient.16 By
performing MTWA screening off beta-blockers, prior studies
may have measured higher MTWA amplitudes than when on
beta-blockers and may have classified a certain proportion
of otherwise MTWA negative patients as positive (i.e., false-
positives). As a result, the predictive power of MTWA for
ventricular arrhythmic events in studies where beta-blocker
therapy was withheld prior to testing may have been sub-
stantially diluted and could account for the wide variation in
MTWA study results. This issue deserves further investiga-
tion and suggests that future trials should consider assessing
MTWA both on and off beta-blockers to confirm the findings
of this study.
The rationale for withholding beta-blocker therapy prior
to MTWA screening has been to decrease the proportion of
indeterminate results, as a negative result requires achieving
heart rates of 110–120 beats per minute and documentation
of no sustained MTWA.27 However, recent studies found that
indeterminate MTWA tests have similar prognostic utility as
positive tests,20,21 even among patients unable to achieve this
heart rate level. This suggests that the protocol requirement
of withholding beta-blocker therapy prior to screening may
be unnecessary, especially if doing so affects the predictive
power of MTWA.
In a recent meta-analysis, Hohnloser et al.28 called into
question the validity of including ICD shocks as a clinical
endpoint in MTWA studies. The authors found that the pre-
dictive power of an abnormal MTWA test result was excellent
among studies with low ICD use and mediocre among studies
with high ICD use. However, in this meta-analysis, we did
not find that the predictive power of an abnormal MTWA
test result differed substantially by ICD use. Our results
likely differed from the Hohnloser meta-analysis because our
study: (1) included only patients with left ventricular systolic
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TABLE 3
Summary of Study Accuracy, Stratified by Whether Beta-Blocker Therapy
Was Withheld Prior to Microvolt T-Wave Alternans Screening
Study Sensitivity, % Specificity, % PPV, % NPV, %
Screening on beta-blockers
Bloomfield25 93 37 14 98
ALPHA14 88 36 10 97
Hohnloser19 89 27 16 94
Klingenheben18 100 35 18 100
SUMMARY 92 36 13 98
Screening off beta-blockers
Chow10 84 35 11 96
ABCD15 75 30 12 90
SCD-HeFT13 79 29 17 88
MASTER12 69 38 13 90
Grimm24 82 29 16 90
SUMMARY 77 33 13 91
Studies continuing beta-blocker therapy during microvolt T-wave alternans
testing were associated with higher sensitivity and NPV for ventricular
arrhythmic events. NPV = negative predictive value; PPV = positive
predictive value.
dysfunction; (2) excluded patients with invasive assessments
of MTWA; and (3) categorized the Sudden Cardiac Death in
Heart Failure Trial (SCD-HeFT) as a low ICD use study, as
only 34% of patients in the MTWA substudy of SCD-HeFT
received an ICD.
While an abnormal MTWA was associated with a greater
than 5-fold increased risk for ventricular arrhythmic events
in studies where beta-blocker therapy was continued during
screening, simultaneously demonstrating that patients with
normal test results have a low event rate is critical in order for
MTWA to be considered for optimal risk stratification of pri-
mary prevention patients for ICD therapy. Indeed, we found
that the NPV was 98% for an abnormal MTWA test result
in studies where beta-blocker therapy was continued during
TABLE 4
Results of All Subgroup Analyses
Studies Pooled Risk
Stratified By (Number) Ratio (95% CI)
Beta-blocker use
Continued during MTWA screening 4 5.39 (2.68–10.84)
Withheld prior to MTWA screening 5 1.40 (1.06–1.84)
Proportion of study patients with ICDs
<40% 6 2.55 (1.18–5.52)
≥40% 3 1.58 (1.03–2.43)
Number of study sites
<10 5 2.51 (1.42–4.43)
≥10 4 1.64 (0.95–2.81)
Publication year
Before 2006 3 2.02 (0.59–6.95)
Since 2006 6 2.01 (1.24–3.26)
Etiology of cardiomyopathy
Ischemic 4 1.71 (1.05–2.79)
Nonischemic 3 2.14 (0.90–5.07)
Ischemic and nonischemic 2 2.55 (0.45–14.45)
The heterogeneity in MTWA studies was best explained by whether beta-
blocker therapy was withheld prior to MTWA screening. The pooled risk
ratios were not as different from one another when studies were stratified by
the proportion of study patients with implantable cardioverter defibrillators
(ICD), number of enrolled sites, publication year, or the etiology of left
ventricular dysfunction. CI = confidence interval.
screening. Based on our prior economic model of MTWA
screening,29 a strategy of implanting ICDs in all eligible pa-
tients, as compared with a strategy of implanting ICDs only
in patients identified as high-risk when the RR is 5 with
an abnormal MTWA test, would yield an incremental cost-
effectiveness ratio of ∼US$150,000 per quality-adjusted life-
year and would not be considered cost-effective. However,
future studies are needed to confirm the accuracy of MTWA
test results when beta-blocker therapy is not withheld prior
to screening before endorsement of their routine use in risk
stratification.
Our study should be interpreted in the context of sev-
eral limitations. We did not have patient-level data to con-
duct an on-treatment analysis or a multivariable analysis.
Additionally, definitions for the study endpoint of ventric-
ular arrhythmic events varied across studies. We were un-
able to examine the association between MTWA and either
mortality or appropriate ICD shocks, as these were not rou-
tinely reported in many studies. Moreover, because we did
not have patient-level data, we were unable to determine
whether some of the heterogeneity across MTWA studies
was due to inclusion of appropriate ICD shocks as part of
a combined arrhythmic endpoint in more recent studies. We
were unable to assess the impact of withholding other medi-
cations with antiadrenergic and antiarrhythmic effects (e.g.,
Vaughan Williams Class III agents) prior to MTWA screen-
ing. However, the majority of patients with left ventricular
dysfunction are not treated with conventional antiarrhythmic
therapy. Finally, while prior studies only examined the acute
effect of intravenous beta-blockers on MTWA amplitude,
it is unclear whether oral beta-blockers would have similar
effects.
In conclusion, an abnormal MTWA test was associated
with a 5-fold increased risk for ventricular arrhythmic events
among primary prevention patients with left ventricular dys-
function in studies where beta-blocker therapy was continued
during MTWA screening, while a weak association was seen
in studies where beta-blocker therapy was withheld prior to
screening. This observation may help explain the inconsistent
results of MTWA studies in this population.
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